Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria

Hermeling, 2004, Structure-immunogenicity relationships of therapeutic proteins, Pharm. Res., 21, 897, 10.1023/B:PHAM.0000029275.41323.a6 Chirino, 2005, Minimizing the immunogenicity of protein therapeutics, Drug Discov. Today, 9, 82, 10.1016/S1359-6446(03)02953-2 Hwang, 2005, Immunogenicity of engineered antibodies, Methods, 36, 3, 10.1016/j.ymeth.2005.01.001 Bugelski, 2004, Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans, Curr. Opin. Mol. Ther., 6, 10 Carter, 2006, Potent antibody therapeutics by design, Nat. Rev. Immunol., 6, 343, 10.1038/nri1837 Laroche, 2000, Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes, Blood, 96, 1425, 10.1182/blood.V96.4.1425 Meyer, 2001, Reduced antibody response to streptavidin through site directed mutagenesis, Protein Sci., 10, 491, 10.1110/ps.19901 Gámez, 2005, Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria, Mol. Therapy, 11, 986, 10.1016/j.ymthe.2005.02.013 Basu, 2006, Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation, Bioconjug. Chem., 17, 618, 10.1021/bc050322y Wang, 2002, Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications, Adv. Drug Deliv. Rev., 54, 547, 10.1016/S0169-409X(02)00027-3 Bailon, 2001, Rational design of a potent, long-lasting form of interferon: a 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C, Bioconjug. Chem., 12, 195, 10.1021/bc000082g De Groot, 2005, De-immunization of therapeutic proteins by T-cell epitope modification, Dev. Biol. (Basel), 122, 171 Tangri, 2002, Rationally engineered proteins or antibodies with absent or reduced immunogenicity, Curr. Med. Chem., 9, 2191, 10.2174/0929867023368647 Donlon, 2004, Hyperphenylalaninemia: phenylalanine hydroxylase deficiency Bickel, 1981, Neonatal mass screening for metabolic disorders: a collaborative study, Eur. J. Pediatr., 137, 133 Levy, 1999, Phenylketonuria: old disease, new approach to treatment, Proc. Natl. Acad. Sci. USA, 96, 1811, 10.1073/pnas.96.5.1811 Sarkissian, 2000, A heteroallelic mutant mouse model: a new orthologue for human hyperphenylalaninemia, Mol. Genet. Metab., 69, 188, 10.1006/mgme.2000.2974 Hoskins, 1982, Phenylalanine ammonia lyase in the management of phenylketonuria: the relationship between ingested cinnamate and urinary hippurate in humans, Res. Commun. Chem. Pathol. Pharmacol., 35, 275 Gilbert, 1985, Molecular cloning of the phenylalanine ammonia lyase gene from Rhodosporidium toruloides in Escherichia coli K-12, J. Bacteriol., 161, 314, 10.1128/JB.161.1.314-320.1985 Sarkissian, 1999, A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase, Proc. Natl. Acad. Sci. USA, 96, 2339, 10.1073/pnas.96.5.2339 Liu, 2002, Study on a novel strategy to treatment of phenylketonuria, Artif. Cells Blood Substit. Immobil. Biotechnol., 30, 243, 10.1081/BIO-120006117 Wang, 2005, Structure-based chemical modification strategy for enzyme replacement treatment of patients with phenylketonuria, Mol. Genet. Metab., 86, 134, 10.1016/j.ymgme.2005.05.012 Snapper, 1940, Cinnamic acid metabolism in man, Proc. Soc. Exp. Biol. Med., 44, 30, 10.3181/00379727-44-11346 Hoskins, 1984, The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study, Biomed. Mass Spectrom., 11, 296, 10.1002/bms.1200110609 Calabrese, 2004, Crystal structure of phenylalanine ammonia lyase: multiple helix dipoles implicated in catalysis, Biochemistry, 43, 11403, 10.1021/bi049053+ Ritter, 2004, Structural basis for the entrance into the phenylpropanoid metabolism catalyzed by phenylalanine ammonia-lyase, Plant Cell, 16, 3426, 10.1105/tpc.104.025288 Schwede, 1999, Crystal structure of histidine ammonia-lyase revealing a novel polypeptide modification as the catalytic electrophile, Biochemistry, 38, 5355, 10.1021/bi982929q Welling, 1985, Prediction of sequential antigenic regions in proteins, FEBS Lett., 188, 215, 10.1016/0014-5793(85)80374-4 Frank, 1996, SPOT synthesis. Epitope analysis with arrays of synthetic peptides prepared on cellulose membranes, Methods Mol. Biol., 66, 149 Kramer, 1998, Synthesis and screening of peptide libraries on continuous cellulose membrane supports, Methods Mol. Biol., 87, 25 Reineke, 1999, Antigen sequence- and library-based mapping of linear and discontinuous protein-protein-interaction sites by spot synthesis, Curr. Top Microbiol. Immunol., 243, 23 Schafer, 1998, Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix Vaccine, 16, 1880, 10.1016/S0264-410X(98)00173-X Martin, 2003, Bioinformatics tools for identifying class I-restricted epitopes, Methods, 29, 289, 10.1016/S1046-2023(02)00351-1 Ganson, 2006, Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase, Arthritis Res. Ther., 8, R12, 10.1186/ar1861 Harris, 2003, Effect of pegylation on pharmaceuticals, Nat. Rev. Drug Discov., 2, 214, 10.1038/nrd1033 Hopp, 1981, Prediction of protein antigenic determinants from amino acid sequences, Proc. Natl. Acad. Sci. USA, 78, 3824, 10.1073/pnas.78.6.3824